Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Advanced Solid Neoplasm 2Solid Tumors 1Renal Insufficiency 1Neoplasm, Residual 1Melanoma 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumors 1Advanced Nonhematologic Malignancies 1

Interventions

Cyclophosphamide 7blinatumomab 6Cytarabine 6fludarabine 5Mercaptopurine 5Methotrexate 4fludarabine phosphate 3Vincristine 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Drug Therapy 3Dexamethasone 3Daunorubicin 3Asparaginase 3Whole-Body Irradiation 2Vindesine 2Thioguanine 2Teniposide 2Stem Cell Transplantation 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Interleukin-2 2Doxorubicin 2Cladribine 2Blood Specimen Collection 2Azacitidine 2tisagenlecleucel 1thymoglobulin 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm, Residual × pevonedistat × Clear all
NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

University of Leipzig

Phase 2 Completed
14 enrolled
Myeloid

Myelodysplastic Syndromes, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡